sugemalimab
cstone pharmaceuticals
['lymphoma', 't-cell lymphoma', 'sugemalimab']
$csphf cstone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/t-cell lymphoma via an oral abstract session at asco 2022 
News and analysis of biomedical, biopharma, biotech, biosciences, pharmaceutical, and technology equities